A rare pathogenic variant identified in a heart transplant recipient with hereditary transthyretin amyloidosis: a case report
Open Access
- 30 November 2023
- journal article
- research article
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 40 (Suppl) , S98-S104
Abstract
Hereditary transthyretin (ATTRv) amyloidosis is a rare and complex genetic disorder that can lead to life-threatening cardiac amyloidosis and rapid disease progression. Early diagnosis and treatment with disease-modifying drugs can improve patient outcomes; however, heart transplantation may be necessary in some patients. We present the unique case of a 65-year-old Korean woman diagnosed with ATTRv amyloidosis after experiencing progressive neurological symptoms, followed by heart failure. Despite the absence of significant symptoms of heart failure, subsequent screening revealed cardiac amyloid infiltration, which caused left ventricular hypertrophy and rapid disease progression. The patient underwent successful heart transplantation, and subsequent genetic testing revealed a pathogenic variant, NM_000371.3:c.425T>C (p.Val142Ala), which affects both the nerves and heart and has not been previously reported in Korea. Our report underscores the potential benefits of heart transplantation in managing advanced ATTRv amyloidosis and emphasizes the need for continued research on the genetic heterogeneity of the disease. Clinicians should consider ATTRv amyloidosis in the differential diagnosis of patients presenting with neurological symptoms and heart failure, particularly in those with a family history of the disease.Keywords
This publication has 8 references indexed in Scilit:
- Real-World Efficacy of Tafamidis in Patients With Transthyretin Amyloidosis and Heart FailureCurrent Problems in Cardiology, 2023
- A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)Amyloid, 2022
- Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year updateOrphanet Journal of Rare Diseases, 2022
- Critical Comparison of Documents From Scientific Societies on Cardiac AmyloidosisJACC, 2022
- Cardiovascular Involvement in Transthyretin Cardiac AmyloidosisHeart Failure Clinics, 2022
- ATTR Amyloidosis: Current and Emerging Management StrategiesJACC: Cardiooncology, 2021
- Prevalence and Outcomes of p.Val142Ile TTR Amyloidosis Cardiomyopathy: A Systematic ReviewCirculation: Genomic and Precision Medicine, 2021
- Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)European Heart Journal, 2019